Professor Paul Kong Thoo Lin
Multitargets drug for Sepsis: Mechanistic studies of drug action through mitigating infection and inflammatory responses associated with sepsis.
People Involved
Dr Graeme Kay g.kay@rgu.ac.uk
Associate Dean for ESCD
Dr Aakash Welgamage Don a.welgamage-don@rgu.ac.uk
Lecturer
Project Description
Sepsis is a life-threatening clinical condition caused by an overreacting immune system fighting an infection. It is often treated with broad-spectrum antibiotics together with anti-inflammatory drugs. However, due to the heterogeneous nature of the disease combined with emerging multi-drug resistance in bacteria, the development of an effective treatment has become inherently difficult. We have studied the anticancer, anti-inflammatory, and antibacterial activity of compounds such as vanillin, naphthalimide and phthalimide, demonstrating great potential as medicinal drug precursors. This project aims to study their mechanisms of action and potentially establish the multitarget-directed hypothesis.
| Status | Project Live |
|---|---|
| Value | £12,499.00 |
| Project Dates | Oct 1, 2023 - Sep 30, 2025 |
You might also like
Multi-targets drug against Alzheimer (AD) disease: Mechanistic studies of drug action through amyloid and associated signalling pathways. Sep 1, 2020 - Dec 31, 2022
The aim of this project is to synthesise a small discrete library of novel compounds based on our lead compound, by applying the methodology developed in our laboratory, and to study the mechanism of action of active one and confirm the multi targe...
Read More about Multi-targets drug against Alzheimer (AD) disease: Mechanistic studies of drug action through amyloid and associated signalling pathways..
Development and characterisation of novel polymer-drug conjugates for the treatment of Alzheimer’s disease Sep 1, 2022 - Aug 31, 2024
Using new polymer-drug compounds to improve the ability to deliver anti-Alzheimer drugs in the body.